LA JOLLA, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell ...
Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, July 31, 2025 ...
GRI Bio, Inc. has received a recommendation from the Independent Data Monitoring Committee to continue its Phase 2a study of GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF) following ...
GRI Bio has announced encouraging six-week interim safety outcomes from the ongoing Phase IIa trial of the small molecule RAR-βɣ dual agonist, GRI-0621, to treat idiopathic pulmonary fibrosis (IPF).
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm - suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities ...
GRI Bio, Inc. (NASDAQ: GRI) today reported interim biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”). Additionally, ...
Hosted on MSN
GRI Bio reports positive study results for chronic lung disease, but stock slumps 20% — what happened?
・The latest findings include RNA-sequencing data showing that GRI-0621 significantly modulated genes associated with lung injury. ・Prior Phase 2a results had already shown favorable safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results